Raymond Carragher

Raymond Carragher

Auto-generated profile, based on publicly available information

Raymond Carragher

University of the West of Scotland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CDCaroline E. Dale
Caroline E. Dale
RTRohan Takhar
Rohan Takhar
RCRaymond Carragher
Raymond Carragher
MKMichail Katsoulis
Michail Katsoulis
FTFatemeh Torabi
Fatemeh Torabi
CCCVD-COVID-UK Consortium
CVD-COVID-UK Consortium
How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management of cardiovascular disease (CVD) is not fully understood. In this study, we used medication data as a proxy for CVD management using routinely collected, de-identified, individual-level data comprising 1.32 billion records of community-dispensed CVD medications from England, Scotland and Wales between April 2018 and July 2021. Here we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes compared to the previous year, for several CVD-related indications, focusing on hypertension, hypercholesterolemia and diabetes. We observed a decline in the dispensing of antihypertensive medications between March 2020 and July 2021, with 491,306 fewer individuals initiating treatment than expected. This decline was predicted to result in 13,662 additional CVD events, including 2,281 cases of myocardial infarction and 3,474 cases of stroke, should individuals remain untreated over their lifecourse. Incident use of lipid-lowering medications decreased by 16,744 patients per month during the first half of 2021 as compared to 2019. By contrast, incident use of medications to treat type 2 diabetes mellitus, other than insulin, increased by approximately 623 patients per month for the same time period. In light of these results, methods to identify and treat individuals who have missed treatment for CVD risk factors and remain undiagnosed are urgently required to avoid large numbers of excess future CVD events, an indirect impact of the COVID-19 pandemic.

10 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JKJoris J Komen
Joris J Komen
APAnton Pottegård
Anton Pottegård
AMAukje Mantel
Aukje Mantel
TFTomas Forslund
Tomas Forslund
PHPaul Hjemdahl
Paul Hjemdahl
OKOlaf H Klungel
Olaf H Klungel
There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant. We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56–0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54–1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59–1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88–2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70–1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42–0.94). These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial. In patients with atrial fibrillation at low stroke-risk from Sweden, Denmark, Scotland, and Norway, treatment with a NOAC was associated with a lower stroke rate compared to no treatment and a lower intracranial haemorrhage rate compared to VKA treatment. NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; HR, hazard ratio; VS, versus.

17 December 2024 in The American Journal of Surgery
Verified
Journal Article
Open access
BLBeatrice Leyaro
Beatrice Leyaro
LHLyz Howie
Lyz Howie
KMKevin McMahon
Kevin McMahon
AAAbdulmajid Ali
Abdulmajid Ali
RCRaymond Carragher
Raymond Carragher
Bariatric surgery is a cornerstone intervention for individuals with severe obesity, offering substantial and sustainable weight loss. This retrospective cohort study included 186 patients with obesity and Type2 diabetes who underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) between 2009 and 2020 ​at University Hospital Ayr. Optimal clinical response weight loss was defined as excess weight loss (%EWL) ≥50 ​% or total weight loss (%TWL) ≥20 ​%. At 2-years post-surgery, 43.6 ​% achieved ≥50 %EWL, and 44.1 ​% achieved ≥20%TWL, with 31.8 ​% maintaining this at 5-years. Depending on the definition used, between 11.2 ​% and 45.9 ​% of patients experienced recurrent weight gain. BMI had significant positive association with %TWL but negative with %EWL (p ​< ​0.05). RYGB had significantly higher %TWL compared to SG (p ​< ​0.05). Most patients experienced weight loss which was maintained over time, however recurrent weight gain was noted. Pre-surgery BMI was significantly associated with weight changes.

24 June 2021 in Pharmaceutical Statistics
Verified
Journal Article
Open access
RCRaymond Carragher
Raymond Carragher
CRChris Robertson
Chris Robertson
Recent approaches to the statistical analysis of adverse event (AE) data in clinical trials have proposed the use of groupings of related AEs, such as by system organ class (SOC). These methods have opened up the possibility of scanning large numbers of AEs while controlling for multiple comparisons, making the comparative performance of the different methods in terms of AE detection and error rates of interest to investigators. We apply two Bayesian models and two procedures for controlling the false discovery rate (FDR), which use groupings of AEs, to real clinical trial safety data. We find that while the Bayesian models are appropriate for the full data set, the error controlling methods only give similar results to the Bayesian methods when low incidence AEs are removed. A simulation study is used to compare the relative performances of the methods. We investigate the differences between the methods over full trial data sets, and over data sets with low incidence AEs and SOCs removed. We find that while the removal of low incidence AEs increases the power of the error controlling procedures, the estimated power of the Bayesian methods remains relatively constant over all data sizes. Automatic removal of low-incidence AEs however does have an effect on the error rates of all the methods, and a clinically guided approach to their removal is needed. Overall we found that the Bayesian approaches are particularly useful for scanning the large amounts of AE data gathered.

7 May 2020 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
RCRaymond Carragher
Raymond Carragher
Tanja MuellerTanja Mueller
Tanja Mueller
MBMarion Bennie
Marion Bennie
CRChris Robertson
Chris Robertson
Clinical trials are the standard approach for evaluating new treatments, but may lack the power to assess rare outcomes. Trial results are also necessarily restricted to the population considered in the study. The availability of routinely collected healthcare data provides a source of information on the performance of treatments beyond that offered by clinical trials, but the analysis of this type of data presents a number of challenges. Hierarchical methods, which take advantage of known relationships between clinical outcomes, while accounting for bias, may be a suitable statistical approach for the analysis of this data. A study of direct oral anticoagulants in Scotland is discussed and used to motivate a modeling approach. A Bayesian hierarchical model, which allows a stratification of the population into clusters with similar characteristics, is proposed and applied to the direct oral anticoagulant study data. A simulation study is used to assess its performance in terms of outcome detection and error rates.

4 December 2020 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
RCRaymond Carragher
Raymond Carragher
CRChris Robertson
Chris Robertson